Cancer Institute A national cancer institute
designated cancer center

Billy W. Loo, Jr., MD, PhD, DABR

Publication Details

  • The Management of Patients With Stage IIIA Non-Small Cell Lung Cancer With N2 Mediastinal Node Involvement JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Martins, R. G., D'Amico, T. A., Loo, B. W., Pinder-Schenck, M., Borghaei, H., Chaft, J. E., Ganti, A. K., Kong, F. (., Kris, M. G., Lennes, I. T., Wood, D. E. 2012; 10 (5): 599-613

    Abstract:

    Patients with stage IIIA non-small cell lung cancer, determined based on involvement of ipsilateral mediastinal lymph nodes, represent the most challenging management problem in this disease. Patients with this stage disease may have very different degrees of lymph node involvement. The pathologic confirmation of this involvement is a key step in the therapeutic decision. The difference in the degree of lymph node compromise has prognostic and treatment implications. Based on multiple considerations, patients can be treated with induction chemotherapy, chemoradiotherapy followed by surgery, or definitive chemoradiotherapy without surgery. Data derived from clinical trials have provided incomplete guidance for physicians and their patients. The best therapeutic plan is achieved through the multidisciplinary cooperation of a team specialized in lung cancer.

    View details for Web of Science ID 000303557700006

    View details for PubMedID 22570291

Stanford Medicine Resources:

Footer Links: